ECSP23025065A - Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas - Google Patents

Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas

Info

Publication number
ECSP23025065A
ECSP23025065A ECSENADI202325065A ECDI202325065A ECSP23025065A EC SP23025065 A ECSP23025065 A EC SP23025065A EC SENADI202325065 A ECSENADI202325065 A EC SENADI202325065A EC DI202325065 A ECDI202325065 A EC DI202325065A EC SP23025065 A ECSP23025065 A EC SP23025065A
Authority
EC
Ecuador
Prior art keywords
heavy chain
antibodies
constant regions
chain constant
modified
Prior art date
Application number
ECSENADI202325065A
Other languages
English (en)
Inventor
Starlynn Clarke
Omid Vafa
Aldred Shelley Force
Schooten Wim Van
Ute Schellenberger
Duy Pham
Katherine Harris
Nathan Trinklein
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of ECSP23025065A publication Critical patent/ECSP23025065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan anticuerpos multiespecíficos humanos de cadena pesada (p. ej., UniAbsTM) que tienen regiones constantes de cadena pesada modificadas que imparten propiedades ventajosas. La invención se refiere además a métodos para preparar dichos anticuerpos, composiciones, incluidas composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión de una o más de las dianas de unión descritas en la presente.
ECSENADI202325065A 2020-04-29 2023-04-05 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas ECSP23025065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017589P 2020-04-29 2020-04-29
US202063108796P 2020-11-02 2020-11-02

Publications (1)

Publication Number Publication Date
ECSP23025065A true ECSP23025065A (es) 2023-06-30

Family

ID=76159995

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI202283174A ECSP22083174A (es) 2020-04-29 2022-10-25 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
ECSENADI202325065A ECSP23025065A (es) 2020-04-29 2023-04-05 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSENADI202283174A ECSP22083174A (es) 2020-04-29 2022-10-25 Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas

Country Status (8)

Country Link
AR (2) AR127513A2 (es)
CA (1) CA3214992A1 (es)
CL (1) CL2022002963A1 (es)
EC (2) ECSP22083174A (es)
TW (2) TW202330622A (es)
UY (3) UY40898A (es)
WO (1) WO2021222578A1 (es)
ZA (1) ZA202211667B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
AU2017316604C1 (en) 2016-08-24 2025-01-30 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
HRP20240767T1 (hr) 2016-09-14 2024-09-13 Teneoone, Inc. Cd3 vezujuća antitijela
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CA3086665A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
AU2020252556B2 (en) 2019-04-05 2026-02-05 Teneobio, Inc. Heavy chain antibodies binding to PSMA
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
MX2024001761A (es) * 2021-08-09 2024-04-29 Harbour Biomed Shanghai Co Ltd Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos.
TW202430553A (zh) 2022-11-24 2024-08-01 中國大陸商上海藥明生物技術有限公司 Psma抗體及其用途
TW202544034A (zh) 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2010224160A1 (en) 2009-03-10 2011-09-22 Biogen Idec Ma Inc. Anti-BCMA antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
EP3628685A1 (en) * 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Human fcrn-binding modified antibodies and methods of use
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
IL313507A (en) * 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
TWI672317B (zh) * 2016-08-16 2019-09-21 Epimab Biotherapeutics, Inc. 單價不對稱串聯Fab雙特異性抗體
HRP20240767T1 (hr) 2016-09-14 2024-09-13 Teneoone, Inc. Cd3 vezujuća antitijela
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR20250012203A (ko) 2017-06-30 2025-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체
CN120058938A (zh) * 2017-10-10 2025-05-30 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
BR112021004680A2 (pt) * 2018-09-21 2021-08-31 Teneobio, Inc. Métodos para purificar anticorpos multiespecíficos heterodiméricos

Also Published As

Publication number Publication date
ECSP22083174A (es) 2022-11-30
AR133615A2 (es) 2025-10-15
ZA202211667B (en) 2023-10-25
CL2022002963A1 (es) 2023-06-30
TW202330622A (zh) 2023-08-01
WO2021222578A1 (en) 2021-11-04
UY39191A (es) 2021-11-30
TW202206462A (zh) 2022-02-16
AR127513A2 (es) 2024-01-31
CA3214992A1 (en) 2021-11-04
UY40003A (es) 2023-03-31
TWI838621B (zh) 2024-04-11
UY40898A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
MX2022013453A (es) Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
ECSP23025065A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
MX2020006494A (es) Anticuerpos de cadena pesada que se unen a cd22.
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
CL2023002284A1 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CO2022015105A2 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2024002258A1 (es) Anticuerpo multiespecífico anti-cd3/cd19; método de producción; composición farmacéutica; y su uso.
UY36922A (es) Inhibidores de asgr
CO2025013396A2 (es) Anticuerpos muc1 y cd16a y métodos de uso
AR122120A1 (es) Moléculas de fijación para el tratamiento de cáncer
AR106572A1 (es) Inhibidores de asgr